EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC

Fengna Yan, Bingbing Zhu, Ke Shi, Yi Zhang, Xuanwei Zeng, Qun Zhang, Zhiyun Yang, Xianbo Wang iD

Cancer Science · 2024-08 · 115 (8) · 2553-2564

DOI: 10.1111/cas.16247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 15.06.2024. Verfasst von Fengna Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, CD8-Positive T-Lymphocytes, Inducible T-Cell Co-Stimulator Protein, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University, The science fundation of Beijing Ditan Hospital, Capital Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 50% of patients with hepatitis B virus‐associated hepatocellular carcinoma (HBV‐HCC) are diagnosed at an advanced stage, which is characterized by immune imbalance between CD8+ T cells and regulatory T (Treg) cells that accelerates disease progression. However, there is no imbalance indicator to predict clinical outcomes. Here, we show that the proportion of CD8+ T cells decreases and Treg cells increases in advanced HBV‐HCC patients. During this stage, CD8+ T cells and Treg cells expressed the coinhibitory molecule PD‐1 and the costimulatory molecule ICOS, respectively. Additionally, the ratio between PD‐1+CD8 and ICOS+Tregs showed significant changes. Patients were further divided into high‐ and low‐ratio groups: PD‐1+CD8 and ICOS+Tregs high‐ (PD‐1/ICOS hi ) and low‐ratio (PD‐1/ICOS lo ) groups according to ratio median. Compared with PD‐1/ICOS lo patients, the PD‐1/ICOS hi group had better clinical prognosis and weaker CD8+ T cells exhaustion, and the T cell‐killing and proliferation functions were more conservative. Surprisingly, the small sample analysis found that PD‐1/ICOS hi patients exhibited a higher proportion of tissue‐resident memory T (T RM ) cells and had more stable killing capacity and lower apoptosis capacity than PD‐1/ICOS lo advanced HBV‐HCC patients treated with immune checkpoint inhibitors (ICIs). In conclusion, the ratio between PD‐1+CD8 and ICOS+Tregs was associated with extreme immune imbalance and poor prognosis in advanced HBV‐HCC. These findings provide significant clinical implications for the prognosis of advanced HBV‐HCC and may serve as a theoretical basis for identifying new targets in immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorCD8-Positive T-LymphocytesInducible T-Cell Co-Stimulator ProteinT-Lymphocytes, RegulatoryLiver NeoplasmsCarcinoma, HepatocellularHumansPrognosisMaleFemaleMiddle AgedHepatitis B virusImmune Checkpoint InhibitorsAdultAgedHepatitis B

Stichwörter der Autor:innen

ICOS+TregsPD‐1+CD8 cellshepatitis B virus‐associated hepatocellular carcinomaimmune imbalancetumor progression

Substanzen

Programmed Cell Death 1 ReceptorInducible T-Cell Co-Stimulator ProteinICOS protein, humanPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Center for Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Institute of Infectious Diseases, Beijing, China.

ORCID-Profile: Xianbo Wang

Förderung

  • Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University
  • The science fundation of Beijing Ditan Hospital, Capital Medical University

Zitieren

APA

Yan, F., Zhu, B., Shi, K., Zhang, Y., Zeng, X., Zhang, Q., Yang, Z., & Wang, X. (2024). Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC. Cancer Science, 115(8), 2553-2564. https://doi.org/10.1111/cas.16247

Vancouver

Yan F, Zhu B, Shi K, Zhang Y, Zeng X, Zhang Q, et al. Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC. Cancer Science. 2024;115(8):2553-2564. doi:10.1111/cas.16247

BibTeX
@article{Yan2024,
  author = {Yan, Fengna and Zhu, Bingbing and Shi, Ke and Zhang, Yi and Zeng, Xuanwei and Zhang, Qun and Yang, Zhiyun and Wang, Xianbo},
  title = {Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {8},
  pages = {2553--2564},
  doi = {10.1111/cas.16247}
}
Kostenlos starten →